Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T61696 | EGFR-IN-57 | ||
EGFR-IN-57 (Compound 25a) 是一种有效的、具有口服活性的EGFR-TK 抑制剂,IC50值为 0.054 μM。EGFR-IN-57 也抑制VEGFR-2、CK2α、topoisomerase IIβ和tubulin polymerization,IC50值分别为 0.087、0.171、0.13 和 3.61 μM。EGFR-IN-57 诱导细胞 G2/M 和 pre-G1 期周期阻滞,诱导癌细胞凋亡 (apoptosis)。 | |||
T78850 |
EGFR/BRAFV600E-IN-3
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR/BRAFV600E-IN-3 是一种针对 EGFR、BRAFV600E 和 EGFRT790M 的抑制剂,其IC50值分别为57 nM、68 nM 和 9.70 nM。它不但能诱导凋亡,还展现出优异的抗氧化能力。 | |||
T81739 |
Multi-target kinase inhibitor 2
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Multi-target kinase inhibitor 2 (compound 5K) 作为一种multi-targeted kinase抑制剂,对EGFR、Her2、VEGFR2和CDK2酶表现出强效活性,IC50值在40至204 nM之间。此化合物对包括HepG2、HeLa、MDA-MB-231 和 MCF-7在内的多种细胞系均显示出显著的细胞毒性,其IC50值分别为41、57、51 和 59 μM。此外,Multi-target kinase inhibitor 2 还能诱导HepG2细胞发生周期阻滞和凋亡 (apoptosis)。 | |||
T35915 |
Erlotinib-13C6
Erlotinib-13C6 |
||
Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1]. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1].Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process[2]... |